BACKGROUND/AIMS: Several trials have demonstrated beneficial effects of statins in some biological activities that go beyond lipid lowering, suggesting that statins might have other therapeutic benefits. However, it remains to be determined whether statin use is correlated with upper gastrointestinal diseases. We investigated the effects of statin therapy on gastroduodenal ulcers or reflux esophagitis (RE) in a case-control study. METHODOLOGY: We identified 120 newly diagnosed gastroduodenal ulcer cases and 146 RE cases from endoscopic examinees in the Gunma Prefectural Cardiovascular Center. Two controls per case were respectively selected according to sex and age and we determined 240 and 292 controls. We calculated odds ratios (OR) and 95% confidence intervals (CI) of peptic ulcer and RE for statin use. RESULTS: Statin use was not associated with the risk of peptic ulcer (OR 1.2; 95% CI 0.7-2.1), and no elevated OR of RE was shown (OR 0.8; 95%CI 0.5-1.4). Ever use of hydrophilic statins, or lipophilic statins was not associated with the risk of peptic ulcer or RE. CONCLUSIONS: Our results suggest that statin use might not be associated with peptic ulcer or RE. These findings indicate that statin therapy might be safe for patients with upper gastrointestinal disease.
BACKGROUND/AIMS: Several trials have demonstrated beneficial effects of statins in some biological activities that go beyond lipid lowering, suggesting that statins might have other therapeutic benefits. However, it remains to be determined whether statin use is correlated with upper gastrointestinal diseases. We investigated the effects of statin therapy on gastroduodenal ulcers or reflux esophagitis (RE) in a case-control study. METHODOLOGY: We identified 120 newly diagnosed gastroduodenal ulcer cases and 146 RE cases from endoscopic examinees in the Gunma Prefectural Cardiovascular Center. Two controls per case were respectively selected according to sex and age and we determined 240 and 292 controls. We calculated odds ratios (OR) and 95% confidence intervals (CI) of peptic ulcer and RE for statin use. RESULTS: Statin use was not associated with the risk of peptic ulcer (OR 1.2; 95% CI 0.7-2.1), and no elevated OR of RE was shown (OR 0.8; 95%CI 0.5-1.4). Ever use of hydrophilic statins, or lipophilic statins was not associated with the risk of peptic ulcer or RE. CONCLUSIONS: Our results suggest that statin use might not be associated with peptic ulcer or RE. These findings indicate that statin therapy might be safe for patients with upper gastrointestinal disease.
Authors: Tawfik Khoury; Amir Mari; Hana Amara; Mohamed Jabaren; Abdulla Watad; Wiliam Nseir; Wisam Sbeit; Mahmud Mahamid Journal: Can J Gastroenterol Hepatol Date: 2019-02-03
Authors: Mohsen Rajabnia; Amir Sadeghi; Saeed Abdi; Mihnea-Alexandru Găman; Mohammad Reza Zali; Niloufar Salehi; Abbas Yadegar; Khaled Rahmani Journal: GE Port J Gastroenterol Date: 2021-09-06
Authors: Ana Filipa Macedo; Fiona Claire Taylor; Juan P Casas; Alma Adler; David Prieto-Merino; Shah Ebrahim Journal: BMC Med Date: 2014-03-22 Impact factor: 8.775